Wednesday, April 24, 2019 - 12:00 to 13:00
MSI Small Lecture Theatre
Professor Ian Gilbert FRSC
Dr Marcus Lee
Wellcome Sanger Institute
The repeated emergence of antimalarial resistance underscores the importance of identifying new drug targets, as well as understanding the genetic architecture of current resistance pathways and any associated fitness costs. We are developing approaches that combine CRISPR-Cas9 genome editing of P. falciparum and next-generation sequencing to accelerate the validation of potential new targets identified from in vitro resistance evolution, to profile compound mode of action, and to address the impact of resistance mutations and genetic background on parasite fitness.